These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8406281)

  • 1. [Is early combined AIDS treatment an advantage? Nucleoside analogs--study will bring enlightenment].
    Moosmann EB
    Fortschr Med; 1993 Aug; 111(24):46. PubMed ID: 8406281
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
    Leal M; Caruz A; Rey C; Lissen E
    Med Clin (Barc); 1996 Nov; 107(19):755. PubMed ID: 9082095
    [No Abstract]   [Full Text] [Related]  

  • 3. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug companies seek trial participants.
    AIDS Alert; 1995 Jun; 10(6):82. PubMed ID: 11362432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better AIDS treatments.
    Minn Med; 1991 Aug; 74(8):42. PubMed ID: 1656183
    [No Abstract]   [Full Text] [Related]  

  • 6. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.
    Gries JM; Troconiz IF; Verotta D; Jacobson M; Sheiner LB
    Clin Pharmacol Ther; 1997 Jan; 61(1):70-82. PubMed ID: 9024175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new HIV/AIDS drug.
    J Ark Med Soc; 1996 Jan; 92(8):407. PubMed ID: 8582889
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies confirm value of early and combination treatments.
    Vazquez E
    Posit Aware; 1995; VI(6):8. PubMed ID: 11363148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Another AIDS drug. Azidothymidine--dideoxycytidine].
    Moosmann EB
    Fortschr Med; 1992 Jun; 110(18):28-30. PubMed ID: 1353746
    [No Abstract]   [Full Text] [Related]  

  • 10. Relevance of AIDS treatment with two nucleoside analogues alone.
    Weidle PJ; Mbidde E; Djomand G; Lackritz EM
    Lancet; 1999 Jun; 353(9169):1989-90. PubMed ID: 10376610
    [No Abstract]   [Full Text] [Related]  

  • 11. AZT/ddC combination may benefit AIDS sufferers.
    Oncology (Williston Park); 1989 Jan; 3(1):107. PubMed ID: 2561878
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Committee recommends clearance for HIVID combination therapy.
    AIDS Patient Care STDS; 1996 Jun; 10(3):186. PubMed ID: 11361630
    [No Abstract]   [Full Text] [Related]  

  • 14. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study results at a glance.
    AIDS Alert; 1995 Nov; 10(11):134. PubMed ID: 11362922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS
    AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
    Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC
    J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.